$19.73
-0.12-0.6%
Last update: Nov 12, 4:03 AM
Denali Therapeutics Inc
DNLINASDAQ
Denali Therapeutics rose 12.6% from $17.52 to $19.73, ahead of the S&P 500's +11.2%. Its worst day was Jul 14 (−14.5%), and its low came Jan 5 at $16.02.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Denali Therapeutics shares fell 10.6%, while the S&P 500 rose 0.7%.
−10.6% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
Denali Therapeutics closed at its lowest level of the year, 8.6% below where the year started.
−1.5% · S&P 500 +0.7%
Denali Therapeutics shares rose 12.5%, while the S&P 500 rose 0.5%.
+12.5%, the year's best day · S&P 500 +0.5%
EPS of $-0.73 beat the $-0.75 estimate on $0.00 revenue (est. $9.0M).
−1.1% · S&P 500 −0.5%
Denali Therapeutic snags FDA accelerated approval for Avlayah for Hunter syndrome, analyst flags strong launch potential.
−12.2% · S&P 500 −1.8%
EPS of $-0.69 beat the $-0.71 estimate on $0.00 revenue (est. $3.8M).
−0.5% · S&P 500 +0.8%
Denali Therapeutics closed at its highest level of the year, 55.3% above where the year started.
+1.9% · S&P 500 +0.8%
EPS of $-0.68 missed the $-0.57 estimate on $3.6M revenue (est. $2.0M).
+0.4% · S&P 500 +0.6%
EPS of $-0.64 missed the $-0.43 estimate on $17.8M revenue (est. $20.8M); Q4 revenue guidance of $30.0M–$32.0M against the $24.8M consensus.
+7.8% · S&P 500 +1.7%
Where it ended: a close of $19.73 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.61, revenue est. $31.9M).
Nothing in the past 12 months.
All DNLI dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DNLI and SPY from Benzinga historical bars. Not investment advice.
